These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14986258)

  • 21. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic resistance tests for the management of postexposure prophylaxis.
    Puro V
    Scand J Infect Dis Suppl; 2003; 106():93-8. PubMed ID: 15000596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
    Demeter LM; Ribaudo HJ; Erice A; Eshleman SH; Hammer SM; Hellmann NS; Fischl MA;
    Clin Infect Dis; 2004 Aug; 39(4):552-8. PubMed ID: 15356820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
    Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
    Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.
    Liuzzi G
    Scand J Infect Dis Suppl; 2003; 106():90-3. PubMed ID: 15000595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updated European recommendations for the clinical use of HIV drug resistance testing.
    Vandamme AM; Sönnerborg A; Ait-Khaled M; Albert J; Asjo B; Bacheler L; Banhegyi D; Boucher C; Brun-Vézinet F; Camacho R; Clevenbergh P; Clumeck N; Dedes N; De Luca A; Doerr HW; Faudon JL; Gatti G; Gerstoft J; Hall WW; Hatzakis A; Hellmann N; Horban A; Lundgren JD; Kempf D; Miller M; Miller V; Myers TW; Nielsen C; Opravil M; Palmisano L; Perno CF; Phillips A; Pillay D; Pumarola T; Ruiz L; Salminen M; Schapiro J; Schmidt B; Schmit JC; Schuurman R; Shulse E; Soriano V; Staszewski S; Vella S; Youle M; Ziermann R; Perrin L
    Antivir Ther; 2004 Dec; 9(6):829-48. PubMed ID: 15651743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing for HIV-1 drug resistance.
    Hanna GJ; Caliendo AM
    Mol Diagn; 2001 Dec; 6(4):253-63. PubMed ID: 11774191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
    Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
    J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.